PMID- 23470460
OWN - NLM
STAT- MEDLINE
DCOM- 20130702
LR  - 20130506
IS  - 1096-0945 (Electronic)
IS  - 0014-4800 (Linking)
VI  - 94
IP  - 3
DP  - 2013 Jun
TI  - Expression analysis of thrombospondin 2 in prostate cancer and benign prostatic 
      hyperplasia.
PG  - 438-44
LID - S0014-4800(13)00032-4 [pii]
LID - 10.1016/j.yexmp.2013.02.002 [doi]
AB  - Thrombospondin 2 (TSP2) is a protein with important roles in different tumor 
      types, mainly related to tumor inhibition. However, there are limiting data 
      regarding TSP2 in prostate cancer (PCa) and benign prostatic hyperplasia (BPH). 
      We aimed to investigate TSP2 transcript and protein expression in tumoral and 
      non-tumoral prostate tissues and cell lines, and its implications for PCa 
      diagnosis and progression. TSP2 transcript expression was evaluated by real time 
      PCR in PCa and BPH tissue samples and in tumoral and non-tumoral cell lines. TSP2 
      protein expression analysis was conducted by immunohistochemistry in a tissue 
      microarray (TMA) containing PCa and BPH tissue samples. TSP2 transcript was 
      down-regulated in PCa tissue samples and cell lines, when compared to BPH and 
      non-tumoral samples (P<0.01). Receiver Operating Curve (ROC) analysis 
      demonstrated that TSP2 transcript levels can better distinguish PCa from BPH 
      tissue samples (P<0.01) than serum PSA levels (P=0.299). TSP2 protein expression 
      has been observed in the cytoplasm of both PCa and BPH epithelial and stromal 
      compartments. TSP2 stromal staining scores were significantly lower in PCa than 
      in BPH tissues (P<0.01), while similar TSP2 epithelial staining patterns were 
      observed in both diseases. Notably, the TSP2 epithelial staining score was 
      significantly correlated to vascular invasion and biochemical recurrence in PCa 
      tissue samples (P<0.05). Our data indicate that TSP2 is down-regulated at PCa 
      tissues and cell lines, especially at stroma compartment, which could be related 
      to PCa progression. TSP2 levels could potentially be applied for differential PCa 
      and BPH diagnosis.
CI  - Copyright (c) 2013 Elsevier Inc. All rights reserved.
FAU - Matos, A R
AU  - Matos AR
AD  - Programa de Carcinogenese Molecular/Programa de Pos Graduacao Stricto Sensu em 
      Oncologia do Instituto Nacional de Cancer, CPQ, Rio de Janeiro, RJ, Brazil.
FAU - Coutinho-Camillo, C M
AU  - Coutinho-Camillo CM
FAU - Thuler, L C S
AU  - Thuler LC
FAU - Fonseca, F P
AU  - Fonseca FP
FAU - Soares, F A
AU  - Soares FA
FAU - Silva, E A
AU  - Silva EA
FAU - Gimba, E R
AU  - Gimba ER
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20130305
PL  - Netherlands
TA  - Exp Mol Pathol
JT  - Experimental and molecular pathology
JID - 0370711
RN  - 0 (DNA, Neoplasm)
RN  - 0 (Thrombospondins)
RN  - 0 (thrombospondin 2)
RN  - EC 3.4.21.77 (Prostate-Specific Antigen)
SB  - IM
MH  - Adenocarcinoma/*genetics/metabolism/pathology
MH  - Cell Line, Tumor
MH  - DNA, Neoplasm/analysis
MH  - Disease Progression
MH  - Down-Regulation
MH  - Epithelial Cells/metabolism/pathology
MH  - *Gene Expression Regulation, Neoplastic
MH  - Humans
MH  - Immunohistochemistry/methods
MH  - Male
MH  - Predictive Value of Tests
MH  - Prostate-Specific Antigen/blood
MH  - Prostatic Hyperplasia/*genetics/metabolism/pathology
MH  - Prostatic Neoplasms/*genetics/metabolism/pathology
MH  - ROC Curve
MH  - Real-Time Polymerase Chain Reaction
MH  - Stromal Cells/metabolism/pathology
MH  - Thrombospondins/*genetics/metabolism
MH  - Tissue Array Analysis
EDAT- 2013/03/09 06:00
MHDA- 2013/07/03 06:00
CRDT- 2013/03/09 06:00
PHST- 2012/10/20 00:00 [received]
PHST- 2013/02/18 00:00 [revised]
PHST- 2013/02/22 00:00 [accepted]
PHST- 2013/03/09 06:00 [entrez]
PHST- 2013/03/09 06:00 [pubmed]
PHST- 2013/07/03 06:00 [medline]
AID - S0014-4800(13)00032-4 [pii]
AID - 10.1016/j.yexmp.2013.02.002 [doi]
PST - ppublish
SO  - Exp Mol Pathol. 2013 Jun;94(3):438-44. doi: 10.1016/j.yexmp.2013.02.002. Epub 
      2013 Mar 5.